Mark T Jennings

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/751625/publications.pdf

Version: 2024-02-01

933447 1281871 2,992 12 10 11 citations h-index g-index papers 12 12 12 5507 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Update on Key Emerging Challenges in Cystic Fibrosis. Medical Principles and Practice, 2014, 23, 393-402.	2.4	2,603
2	Takotsubo Syndrome in the Setting of COVID-19. JACC: Case Reports, 2020, 2, 1321-1325.	0.6	122
3	An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor. Annals of the American Thoracic Society, 2017, 14, 1662-1666.	3.2	59
4	Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 624-630.	0.7	43
5	Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 357-363.	0.7	35
6	Cystic fibrosis transmembrane conductance regulator modulators reduce the risk of recurrent acute pancreatitis among adult patients with pancreas sufficient cystic fibrosis. Pancreatology, 2019, 19, 1023-1026.	1.1	33
7	Risk factors for persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Journal of Cystic Fibrosis, 2017, 16, 681-686.	0.7	28
8	Frequency of small-colony variants and antimicrobial susceptibility of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients. Diagnostic Microbiology and Infectious Disease, 2018, 90, 296-299.	1.8	26
9	Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis—the PMEP trial: study protocol for a randomized controlled trial. Trials, 2014, 15, 223.	1.6	21
10	Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies. Annals of the American Thoracic Society, 2018, 15, 897-902.	3.2	19
11	Year in review 2017: Interventional pulmonology, lung cancer, pleural disease and respiratory infections. Respirology, 2018, 23, 628-635.	2.3	3
12	Low rates of macrolide-resistant Mycobacterium avium complex in cystic fibrosis despite chronic azithromycin therapy. Journal of Cystic Fibrosis, 2021, 20, 555-557.	0.7	0